EAM Investors’s Milestone Scientific MLSS Stock Holding History

EAM Investors’s Portfolio MLSS Stock Details MLSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-314,400	Closed	-$1.12M	–	383
2021 Q1	$1.12M	Buy	+314,400	New	+$1.08M	0.17%	289
2020 Q2	–	Sell	-565,071	Closed	-$706K	–	297
2020 Q1	$706K	Buy	565,071 +22,560	+4%	+$40.7K	0.22%	179
2019 Q4	$754K	Buy	+542,511	New	+$644K	0.17%	223

Other funds holding MLSS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

TEE

Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

EAM Investors's MLSS Position: Q2 2021 in Review

EAM Investors sold out of Milestone Scientific (MLSS) in Q2 2021, closing a stake of 314,400 shares — an estimated $1.12M sold.

EAM Investors first reported a position in MLSS in Q4 2019 and held it in 3 quarters. The position peaked at $1.12M in Q1 2021. 45 funds tracked by Wall St. Rank hold MLSS as of Q2 2021.

EAM Investors reported no remaining Milestone Scientific position as of Q2 2021 after selling out during the quarter.
EAM Investors sold 314,400 Milestone Scientific shares in Q2 2021, an estimated $1.12M.
EAM Investors first reported a position in Milestone Scientific in Q4 2019 and held it in 3 quarters.
EAM Investors's Milestone Scientific position peaked at $1.12M in Q1 2021.
45 funds tracked by Wall St. Rank held Milestone Scientific as of Q2 2021.

Based on EAM Investors's 13F filing for Q2 2021, filed 13 Aug 2021.